Immunomodulatory compositions containing an...

Details Immunomodulatory compositions containing an... Immunomodulatory compositions containing an...

2007-05-29

2007-05-29

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C424S193100, C536S023100

Reexamination Certificate

active

09713136

ABSTRACT:
The invention provides classes of immunomodulatory compositions which comprise an average of one or more immunostimulatory sequence (ISS) containing polynucleotide conjugated, or attached, to antigen. The extent of conjugation affects immunomodulatory properties, such as extent of antigen-specific antibody formation, including Th1-associated antibody formation, and thus these various conjugate classes are useful for modulating the type and extent of immune response. The invention also includes methods of modulating an immune response using these compositions.

REFERENCES:
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 4910300 (1990-03-01), Urdea et al.
patent: 4948882 (1990-08-01), Ruth
patent: 5015733 (1991-05-01), Smith et al.
patent: 5093232 (1992-03-01), Urdea et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5391723 (1995-02-01), Priest
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 6225292 (2001-05-01), Raz et al.
patent: 6498148 (2002-12-01), Raz
patent: 6534062 (2003-03-01), Raz et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 0 468 520 (1992-01-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55609 (1998-12-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/62923 (1999-12-01), None
Hirschwehr et al J Allergy Clin Immunol 101: 196-206, 1995.
Ngo et al, in The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Stryer et al, in Biochemistry, W.H. Freeman and COmpany, New York, pp. 31-33, 1988.
Yamada et al, J Immunology 169: 5590-5594, 2002.
Segal et al, J Immunology 164: 5683-88, 2000.
Chatel et al, Allergey 58: 641-647, 2003.
Klinman et al, Vaccine 17: 19-25, Jan. 1999.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Agrawal et al. (1986). “Efficient methods for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides,”Nucleic Acids Res.14:6227-6245.
Ahmeida et al. (1993). “Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice,”Vaccine11(13):1302-1309.
Aramaki et al. (1995). “Interferon -γ inductive effect of liposomes as an immunoadjuvant,”Vaccine13(18):1809-1814.
Asanuma et al. (1996). “Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration,”Vaccine13(1):3-5.
Atherton et al. (1981). “Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method,”Hoppe-Seylers Z. Physiol. Chem.362:833-839.
Ballas et al. (1996). “Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA,”J.Immunol.157:1840-1845.
Beaucage, Serge L. (1993). “Oligodeoxyribonucleotides synthesis,” Chapter 3in Methods in Molecular Biology: Protocols for Oligonucleotides and Analogsvol. 20, Agrawal, Sudhir, ed. Humana Press: pp. 33-61.
Benoit et al. (1987). “Peptides. Strategies for antibody production and radioimmunoassays,”Neuromethods6:43-72.
Bischoff et al. (1987). “Introduction of 5′-terminal functional groups into synthetic oligonucleotides for selective immobilization,”Analytical Biochemistry164:336-344.
Blanks, Robert and McLaughlin, Larry W. (1988). “An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins,”Nucleic Acids Res.16(21):10283-10299.
Bliss et al. (1996). “IL-12, as an adjuvant, promotes a T helper 1 cell, but does not supress a T helper 2 cell recall response,”J. Immunol.156:887-894.
Bohle et al. (1999). “Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18, and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro,”Eur. J. Immunol.29:2344-2353.
Boujrad et al. (1993). “Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholestrol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor,”Proc. Natl. Acad. Sci. USA90:5728-5731.
Branda et al. (1993). “Immune stimulation by an antisense oligomer complementary to therevgene of HIV-1,”Biochem. Pharmacol.45(10):2037-2043.
Branda et al. (1996). “Amplification of antibody production by phosphorothioate oligodeoxynucleotides,”J. Lab. Clin. Med.128(3):329-338.
Braun et al. (1988). “Immunogenic duplex nucleic acids are nuclease resistant,”J. Immunol.141:2084-2089.
Brazolot Millan et al. (1998) “CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice,”Proc. Natl. Acad. Sci. USA95:15553-15558.
Breiteneder et al. (1989). “The gene coding for the major birch pollen allergenBetvlis highly homologous to a pea disease resistance response gene,”EMBO J.8(7):1935-1938.
Broide et al. (1998). “Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice,”J. Immunol.161:7054-7062.
Broide and Raz (1999). “DNA-based immunization for asthma,”Int. Arch. Allergy Immunol.118:453-456.
Carson and Raz (1997). “Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination,”J. Exp. Med.186(10):1621-1622.
Chace et al. (1997). “Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12,”Clin. Immunol. and Immunopathol.84(2):185-193.
Chaturvedi et al. (1996). “Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages,”Nucleic Acids Res.24(12):2318-2323.
Chen et al. (1999). “Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs,”Vaccine17:653-659.
Chu et al. (1997). “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity,”J. Exp. Med.186(10):1623-1631.
Chua et al. (1988). “Sequence analysis of cDNA coding for a major house dust mite allergen,Der p1 homology with cysteine proteases,”J. Exp. Med.167:175-182.
Chua et al. (1990). “Expression ofDermatophagoides pteronyssinusallergen,Der pII, inEscherichia coliand the binding studies with human IgE,”Int. Arch. Allergy Appl. Immunol.91:124-129.
Connolly, Bernard A. (1985). “Chemical synthesis of oligonucleotides containing a free sulphydryl group and subsequent attachment of thiol specific probes,”Nucleic Acids Res.13(12):4485-4502.
Connolly, Bernard A. (1987). “The synthesis of oligonucleotides containing a primary amino group at the 5′-terminus,”Nucleic Acids Res.15(7):3131-3139.
Corey et al. (1987). “Generation of a hybrid sequence-specific

Affiliated with

Also associated with

Rating

Immunomodulatory compositions containing an... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunomodulatory compositions containing an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory compositions containing an... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3783397